Published in Alzheimers Res Ther on July 14, 2010
Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet (2011) 1.75
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. PLoS One (2012) 1.02
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease. Cell Mol Life Sci (2014) 1.01
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem (2011) 0.99
Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease. Int J Mol Sci (2013) 0.95
Advances in ion mobility spectrometry-mass spectrometry reveal key insights into amyloid assembly. Biochim Biophys Acta (2012) 0.94
The Role of Alzheimer's and Cerebrovascular Pathology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer's Disease. J Alzheimers Dis (2015) 0.90
The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev (2013) 0.89
Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Biomed Res Int (2013) 0.89
Protein Quality Control by Molecular Chaperones in Neurodegeneration. Front Neurosci (2017) 0.87
Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed Res Int (2014) 0.87
Normal cognition in transgenic BRI2-Aβ mice. Mol Neurodegener (2013) 0.86
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo. J Biol Chem (2012) 0.84
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Front Aging Neurosci (2013) 0.83
Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy. Cell Mol Life Sci (2014) 0.82
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease. Pharmaceuticals (Basel) (2012) 0.81
Toward more predictive genetic mouse models of Alzheimer's disease. Brain Res Bull (2015) 0.79
Activated scavenger receptor A promotes glial internalization of aβ. PLoS One (2014) 0.79
Conformational Dynamics of Specific Aβ Oligomers Govern Their Ability To Replicate and Induce Neuronal Apoptosis. Biochemistry (2016) 0.78
Elucidating molecular mass and shape of a neurotoxic Aβ oligomer. ACS Chem Neurosci (2014) 0.78
A structure-toxicity study of Aß42 reveals a new anti-parallel aggregation pathway. PLoS One (2013) 0.77
Repair or Destruction: An Intimate Liaison Between Ubiquitin Ligases and Molecular Chaperones in Proteostasis. FEBS Lett (2017) 0.77
The elusive nature and diagnostics of misfolded Aβ oligomers. Front Chem (2015) 0.76
Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein. PLoS One (2012) 0.76
Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes. Cell Mol Life Sci (2015) 0.76
Sodium dodecyl sulphate modulates the fibrillation of human serum albumin in a dose-dependent manner and impacts the PC12 cells retraction. Colloids Surf B Biointerfaces (2014) 0.75
The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. J Psychiatry Neurosci (2017) 0.75
Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci (2016) 0.75
Interaction of the amyloid β peptide with sodium dodecyl sulfate as a membrane-mimicking detergent. J Biol Phys (2016) 0.75
Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity. ACS Chem Neurosci (2015) 0.75
The A2V mutation as a new tool for hindering Aβ aggregation: A neutron and x-ray diffraction study. Sci Rep (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature (2007) 10.02
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods (1989) 9.42
3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem (1997) 7.62
Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins (2000) 7.61
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem (1997) 5.07
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem (1999) 4.64
Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol (1997) 4.16
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci (1999) 3.92
Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem (1996) 3.84
The crystal structure of diphtheria toxin. Nature (1992) 3.80
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins (2004) 3.63
In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res (1991) 3.45
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A (1986) 3.41
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol (2001) 3.26
Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets. Structure (2003) 3.18
Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem (1996) 2.93
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol (2002) 2.92
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc (2004) 2.79
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem (1997) 2.62
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J (2007) 2.39
Amyloid adhesins are abundant in natural biofilms. Environ Microbiol (2007) 2.35
The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD / NMR study. J Mol Biol (2007) 2.35
Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem (1996) 2.34
Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol (1995) 2.33
Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry (2009) 2.31
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry (2008) 2.26
The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol (2000) 2.26
Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci (2000) 2.23
Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform. J Am Chem Soc (2005) 2.19
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem (2001) 2.14
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A (2009) 2.14
Prediction of amyloid fibril-forming proteins. J Biol Chem (2000) 2.12
Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. Biochem J (2009) 2.07
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox). Eur J Biochem (2001) 2.02
Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry (2006) 1.96
Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging (1995) 1.90
Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging (2008) 1.89
Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur J Biochem (1995) 1.80
Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem (2004) 1.79
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci (2008) 1.71
Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Q Rev Biophys (2008) 1.67
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Amyloid-beta aggregation. Neurodegener Dis (2007) 1.57
Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci (2005) 1.56
Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci (2004) 1.55
Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Proc Natl Acad Sci U S A (2007) 1.55
Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem (2009) 1.52
Protein-DNA and protein-hormone interactions in prealbumin: a model of the thyroid hormone nuclear receptor? Nature (1977) 1.51
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J (2002) 1.48
Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol (2008) 1.47
The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem (2008) 1.46
Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry (1999) 1.44
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Eng Des Sel (2009) 1.38
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging (2010) 1.32
A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils. Nat Struct Biol (2000) 1.31
Conformational transition of amyloid beta-peptide. Proc Natl Acad Sci U S A (2005) 1.28
The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem (1995) 1.27
Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res (2008) 1.26
Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis (2005) 1.26
Surface structure of amyloid-beta fibrils contributes to cytotoxicity. Biochemistry (2007) 1.23
Purification and characterization of brain clusterin. Biochem Biophys Res Commun (1994) 1.21
Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis (2007) 1.20
Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci (2004) 1.19
Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Ann N Y Acad Sci (2005) 1.17
Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40. J Biol Chem (2005) 1.16
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol (2004) 7.02
The FoldX web server: an online force field. Nucleic Acids Res (2005) 6.30
PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res (2006) 3.04
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol (2011) 2.94
Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods (2010) 2.74
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J (2012) 2.72
SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. Nucleic Acids Res (2005) 2.69
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J (2007) 2.39
Prediction of water and metal binding sites and their affinities by using the Fold-X force field. Proc Natl Acad Sci U S A (2005) 2.31
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
The stability effects of protein mutations appear to be universally distributed. J Mol Biol (2007) 2.25
Protein aggregation and amyloidosis: confusion of the kinds? Curr Opin Struct Biol (2006) 2.10
A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J Mol Biol (2004) 2.05
Analysis of protein processing by N-terminal proteomics reveals novel species-specific substrate determinants of granzyme B orthologs. Mol Cell Proteomics (2008) 2.01
SNPeffect v2.0: a new step in investigating the molecular phenotypic effects of human non-synonymous SNPs. Bioinformatics (2006) 1.69
A graphical interface for the FoldX forcefield. Bioinformatics (2011) 1.50
SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants. Nucleic Acids Res (2011) 1.44
Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeffect and PupaSuite databases. Nucleic Acids Res (2007) 1.43
Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics (2011) 1.37
PepX: a structural database of non-redundant protein-peptide complexes. Nucleic Acids Res (2009) 1.35
Recognizing and defining true Ras binding domains II: in silico prediction based on homology modelling and energy calculations. J Mol Biol (2005) 1.33
Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat (2008) 1.31
Proteome-wide substrate analysis indicates substrate exclusion as a mechanism to generate caspase-7 versus caspase-3 specificity. Mol Cell Proteomics (2009) 1.27
Structural basis for increased toxicity of pathological aβ42:aβ40 ratios in Alzheimer disease. J Biol Chem (2011) 1.26
Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat (2007) 1.20
Computational design of peptide ligands. Trends Biotechnol (2011) 1.19
A systems biology perspective on protein structural dynamics and signal transduction. Curr Opin Struct Biol (2005) 1.09
Quantifying information transfer by protein domains: analysis of the Fyn SH2 domain structure. BMC Struct Biol (2008) 1.05
Implications of 3D domain swapping for protein folding, misfolding and function. Adv Exp Med Biol (2012) 1.04
Protein sequences encode safeguards against aggregation. Hum Mutat (2009) 1.04
Reconstruction of protein backbones from the BriX collection of canonical protein fragments. PLoS Comput Biol (2008) 1.04
Protein-peptide interactions adopt the same structural motifs as monomeric protein folds. Structure (2009) 1.04
Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol (2005) 1.02
α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem (2012) 1.02
Genome-wide prediction of SH2 domain targets using structural information and the FoldX algorithm. PLoS Comput Biol (2008) 1.02
Increased monomerization of mutant HSPB1 leads to protein hyperactivity in Charcot-Marie-Tooth neuropathy. J Biol Chem (2010) 1.01
Accurate prediction of DnaK-peptide binding via homology modelling and experimental data. PLoS Comput Biol (2009) 1.01
A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease. Protein Eng Des Sel (2011) 0.99
BriX: a database of protein building blocks for structural analysis, modeling and design. Nucleic Acids Res (2010) 0.98
Structural diversity of PDZ-lipid interactions. Chembiochem (2010) 0.93
An evolutionary trade-off between protein turnover rate and protein aggregation favors a higher aggregation propensity in fast degrading proteins. PLoS Comput Biol (2011) 0.92
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell (2013) 0.91
Protein-peptide complex prediction through fragment interaction patterns. Structure (2013) 0.91
Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide pool. J Biol Chem (2012) 0.90
Protein aggregation in bacteria: the thin boundary between functionality and toxicity. Microbiology (2013) 0.89
Using structural bioinformatics to investigate the impact of non synonymous SNPs and disease mutations: scope and limitations. BMC Bioinformatics (2009) 0.89
Protein design with fragment databases. Curr Opin Struct Biol (2011) 0.88
Aggregation gatekeepers modulate protein homeostasis of aggregating sequences and affect bacterial fitness. Protein Eng Des Sel (2012) 0.87
Predicting aggregation-prone sequences in proteins. Essays Biochem (2014) 0.85
Aggregation prone regions and gatekeeping residues in protein sequences. Curr Top Med Chem (2012) 0.84
Exploring the sequence-structure relationship for amyloid peptides. Biochem J (2013) 0.82
Surfing on protein folding energy landscapes. Proc Natl Acad Sci U S A (2002) 0.82
Peptides based on the presenilin-APP binding domain inhibit APP processing and Aβ production through interfering with the APP transmembrane domain. FASEB J (2012) 0.82
A comparative analysis of the aggregation behavior of amyloid-β peptide variants. FEBS Lett (2012) 0.82
ALS precursor finally shaken into fibrils. Proc Natl Acad Sci U S A (2008) 0.81
Amyloids or prions? That is the question. Prion (2015) 0.80
Folding and association of the human cell cycle regulatory proteins ckshs1 and ckshs2. Biochemistry (2002) 0.80
Hybrid N-glycans on the host protective activation-associated secreted proteins of Ostertagia ostertagi and their importance in immunogenicity. Mol Biochem Parasitol (2008) 0.80